Neoadjuvant Anbenitamab Meets Primary Endpoint in Ph 3 HER2-Positive Breast Cancer Trial
Anbenitamab Injection (‘‘KN026’’) in combination with Docetaxel for Injection (Albumin-bound) (‘‘HB1801’’) independently developed by the Group, has met the pre-specified primary endpoint of total pathological complete response (‘‘tpCR’’) in a Phase III clinical study (Study Protocol No.: KN026–004) for the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer, and the results are highly statistically and clinically significant.
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000